, 0,78 pour respectivement le MCO, l'IMCO et la HAD. Par contre, cette classe ne diminue la durée d'hospitalisation augmente, et ce, quel que soit le secteur considéré, vol.87

L. Enfin and . Fait-d, avoir été hospitalisé dans un établissement public est très peu associé avec la probabilité d'être hospitalisé en MCO avec un OR de 1,1 alors qu'en IMCO, aucune association n'a été mise en évidence

, Enfin, nous avons inclus dans les modèles multivariés les variables décrivant l'infection

, Coeur

, Pour le modèle logistique, l'effet de chaque variable sur la probabilité d'être hospitalisé est exprimé par un odd-ratio (OR), Lecture : Pour chaque modèle 2 résultats sont obtenus

, Annexes Annexe 1 Sélection des catégories infections d'intérêt avec leurs codes CIM-10

, Infections des voies respiratoires basses J13-J16%, p.90

, Annexe 3 Résistances aux antibiotiques et les codes CIM-10 associés. Résistance Codes CIM-10 associés Pénicilline U82.0, U82.0+0

, Methicilline U82.1-U82.18, U82.100, U82.10+0, U82.180 e, vol.82, pp.18-18

, Productrices de bêta-lactamases à spectre élargi U82.2, U82, vol.20

, Autres résistances aux ?-lactamines U82.8, U82.80, U82.8+0, U82.9, U82.9+0

, Quinolone U83.2, U83.20, U83.2+0

, Multiples antibiotiques U83.7, U83.78, U83.780 e , U83.78+0 e Bactéries hautement résistantes émergentes U83, vol.70

, BMR (Bactérie Multirésistante) U83.71, U83.710

, Autres et non spécifiés U83.8, U83.80, U83.8+0, U83.9

, Coeur, issue.0

. Oms-|-qu, est-ce que la résistance aux antimicrobiens?, 2019.

H. C. Davison, M. Woolhouse, and J. C. Low, What is antibiotic resistance and how can we measure it?, Trends Microbiol, vol.8, pp.554-563, 2000.

H. Goossens, M. Ferech, R. Vander-stichele, M. Elseviers, . Esac-project et al., Outpatient antibiotic use in Europe and association with resistance: a cross-national database study, Lancet Lond Engl, vol.365, pp.579-87, 2005.

W. C. Albrich, D. L. Monnet, and S. Harbarth, Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes, Emerg Infect Dis, vol.10, pp.514-521, 2004.

, Bien utiliser les antibiotiques -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.

R. Laxminarayan, A. Duse, C. Wattal, A. Zaidi, H. Wertheim et al., Antibiotic resistance-the need for global solutions, Lancet Infect Dis, vol.13, pp.1057-98, 2013.

, WHO Global Strategy for Containment of Antimicrobial Resistance, p.105

T. T. Yoshikawa, Antimicrobial Resistance and Aging: Beginning of the End of the Antibiotic Era?, J Am Geriatr Soc, vol.50, pp.226-235, 2002.

A. Cassini, L. D. Högberg, D. Plachouras, A. Quattrocchi, A. Hoxha et al., Attributable deaths and disability-adjusted life-years caused by infections with antibioticresistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, Lancet Infect Dis, vol.19, pp.56-66, 2019.

, Center for Disease Control and Prevention. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013.

J. Taylor, M. Hafner, E. Yerushalmi, R. Smith, J. Bellasio et al., Estimating the economic costs of antimicrobial resistance, 2014.

E. Tacconelli, N. Magrini, . Global, . List, . Antibiotic-resistant et al., , vol.7, 2017.

, Annual Report of the European Antimicrobial Resistance Surveillance Network (EARSNet), European Centre for Disease Prevention and Control, p.108, 2017.

I. Arnaud, Surveillance du réseau de surveillance des bactéries multi-résistantes aux antibiotiques (BMR) de 2012 à, vol.4, 2016.

M. Opatowski, P. Tuppin, K. Cosker, M. Touat, G. De-lagasnerie et al., Hospitalisations with infections related to antimicrobial-resistant bacteria from the French nationwide hospital discharge database, Epidemiol Infect, vol.147, p.144, 2016.

J. B. Kaper, J. P. Nataro, and H. Mobley, Pathogenic Escherichia coli, Nat Rev Microbiol, vol.2, pp.123-163, 2004.

. Cmit and . Ecn, PILLY: maladies infectieuses et et tropicales. Place of publication not identified: MED-LINE EDITIONS -EDUC, 2017.

M. Colomb-cotinat, J. Lacoste, C. Brun-buisson, V. Jarlier, B. Coignard et al., Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), Antimicrob Resist Infect Control, vol.5, p.56, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01449337

R. Leistner, A. Bloch, C. Sakellariou, P. Gastmeier, and F. Schwab, Costs and length of stay associated with extended-spectrum ?-lactamase production in cases of Escherichia coli bloodstream infection, J Glob Antimicrob Resist, vol.2, pp.107-116, 2014.

E. Esteve-palau, G. Solande, F. Sánchez, L. Sorlí, M. Montero et al., Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study, J Infect, vol.71, pp.667-74, 2015.

M. Wu, X. Li, Y. Tang, M. Sussman, D. Liu et al., Chapter 87 -Klebsiella pneumoniae and Pseudomonas aeruginosa, Mol Med Microbiol Second Ed, pp.1547-64, 2015.

M. J. Neidell, B. Cohen, Y. Furuya, J. Hill, C. Y. Jeon et al., Costs of Healthcare-and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible Organisms, Clin Infect Dis, vol.55, pp.807-822, 2012.

S. H. Macvane, L. O. Tuttle, and D. P. Nicolau, Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection, J Hosp Med, vol.9, pp.232-240, 2014.

A. J. Stewardson, A. Allignol, J. Beyersmann, N. Graves, M. Schumacher et al., The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, Eurosurveillance, vol.21, p.30319, 2010.

S. Y. Park, J. S. Son, I. H. Oh, J. M. Choi, and M. S. Lee, Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores, Infection, vol.39, pp.141-148, 2011.

W. Branch-elliman, G. M. Lee, T. H. Golen, H. S. Gold, L. M. Baldini et al., Health and Economic Burden of Post-Partum Staphylococcus aureus Breast Abscess, PLOS ONE, vol.8, p.73155, 2013.

R. S. Campbell, M. F. Emons, J. Mardekian, D. Girgenti, M. Gaffney et al., Adverse Clinical Outcomes and Resource Utilization Associated with Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Infections after Elective Surgery, Surg Infect, vol.16, pp.543-52, 2015.

R. E. Nelson, M. H. Samore, M. Jones, T. Greene, V. W. Stevens et al., Reducing Timedependent Bias in Estimates of the Attributable Cost of Health Care-associated Methicillinresistant Staphylococcus aureus Infections: A Comparison of Three Estimation Strategies, Med Care, vol.53, pp.827-861, 2015.

C. Kim, H. Kim, M. Oh, Y. Kim, and A. Kim, The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study, The KIND Study group (Korea Infectious Diseases Study group), vol.14, p.590, 2014.

B. Y. Lee, A. Singh, M. Z. David, S. M. Bartsch, R. B. Slayton et al., The economic burden of community-associated methicillin-resistant Staphylococcus aureus

, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.19, pp.528-564, 2013.

C. Chaix, I. Durand-zaleski, C. Alberti, and C. Brun-buisson, Control of Endemic Methicillin-Resistant Staphylococcus aureus: A Cost-Benefit Analysis in an Intensive Care Unit, JAMA, vol.282, pp.1745-51, 1999.

S. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and V. G. Fowler, Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management, Clin Microbiol Rev, vol.28, pp.603-61, 2015.

D. Pittet, S. Hugonnet, S. Harbarth, P. Mourouga, V. Sauvan et al., Effectiveness of a hospital-wide programme to improve compliance with hand hygiene, Infection Control Programme. Lancet Lond Engl, vol.356, pp.1307-1319, 2000.

M. L. Grayson, L. J. Jarvie, R. Martin, P. Johnson, M. E. Jodoin et al.,

, Med J Aust, vol.188, pp.633-673, 2008.

M. Touraine, Tackling antimicrobial resistance in France, The Lancet, vol.387, pp.2177-2186, 2016.

J. Carlet and L. E. Coz-p, Rapport du groupe de travail spécial pour la préservation des antibiotiques, p.150

L. Roope, R. D. Smith, K. B. Pouwels, J. Buchanan, L. Abel et al., The challenge of antimicrobial resistance: What economics can contribute, Science, vol.364, p.4679, 2019.

P. François, D. Bertrand, C. Beden, J. Fauconnier, and F. Olive, Évaluation du taux de réadmissions précoces comme indicateur de la qualité des soins à l'hôpital, Rev Epidémiologie Santé Publique, vol.49, p.183, 2008.

C. M. Ashton, D. Junco, D. J. Souchek, J. Wray, N. P. Mansyur et al., The association between the quality of inpatient care and early readmission: a meta-analysis of the evidence, Med Care, vol.35, pp.1044-59, 1997.

J. Coast, R. D. Smith, and M. R. Millar, Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?, Health Econ, vol.5, pp.217-243, 1996.

D. H. Howard and R. D. Scott, The Economic Burden of Drug Resistance, Clin Infect Dis, vol.41, pp.283-289, 2005.

K. Eggleston, R. Zhang, and R. J. Zeckhauser, The Global Challenge of Antimicrobial Resistance: Insights from Economic Analysis, Int J Environ Res Public Health, vol.7, pp.3141-3150, 2010.

J. B. Horowitz and H. B. Moehring, How property rights and patents affect antibiotic resistance, Health Econ, vol.13, pp.575-83, 2004.

J. Coast, R. D. Smith, and M. R. Millar, An economic perspective on policy to reduce antimicrobial resistance, Soc Sci Med, vol.46, pp.29-38, 1998.

M. Woolhouse and J. Farrar, Policy: An intergovernmental panel on antimicrobial resistance, Nat News, vol.509, p.555, 2014.

R. Smith and J. Coast, The true cost of antimicrobial resistance, BMJ, vol.346, p.1493, 2013.

G. Clabaugh and M. M. Ward, Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost, Value Health J Int Soc Pharmacoeconomics Outcomes Res, vol.11, pp.13-21, 2008.

C. Jo, Cost-of-illness studies: concepts, scopes, and methods, Clin Mol Hepatol, vol.20, pp.327-364, 2014.

G. U. , , 2019.

L. L. Maragakis, E. N. Perencevich, and S. E. Cosgrove, Clinical and economic burden of antimicrobial resistance, Expert Rev Anti Infect Ther, vol.6, pp.751-63, 2008.

E. Lautenbach, J. B. Patel, W. B. Bilker, P. H. Edelstein, and N. O. Fishman, Extended-Spectrum ?-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on Outcomes, Clin Infect Dis, vol.32, pp.1162-71, 2001.

T. P. Lodise, P. S. Mckinnon, L. Swiderski, and M. J. Rybak, Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia, Clin Infect Dis, vol.36, pp.1418-1441, 2003.

E. H. Ibrahim, G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef,

Y. Carmeli, G. Eliopoulos, E. Mozaffari, and M. Samore, Health and Economic Outcomes of Vancomycin-Resistant Enterococci, Arch Intern Med, vol.162, pp.2223-2231, 2002.

D. Frasca, C. Dahyotfizelier, and O. Mimoz, La colistine en réanimation. Réanimation, vol.17, pp.251-259, 2008.

K. Phe, M. L. Johnson, H. R. Palmer, and V. H. Tam, Validation of a Model To Predict the Risk of Nephrotoxicity in Patients Receiving Colistin, Antimicrob Agents Chemother, vol.58, pp.6946-6954, 2014.

E. D. Cock, S. Sorensen, F. Levrat, J. Besnier, M. Dupon et al.,

C. Hübner, N. Hübner, K. Hopert, S. Maletzki, and S. Flessa, Analysis of MRSA-attributed costs of hospitalized patients in Germany, Eur J Clin Microbiol Infect Dis, vol.33, pp.1817-1839, 2014.

E. Joo, K. R. Peck, Y. E. Ha, Y. Kim, Y. Song et al., Impact of acute kidney injury on mortality and medical costs in patients with meticillin-resistant Staphylococcus aureus bacteraemia: a retrospective, multicentre observational study, J Hosp Infect, vol.83, pp.300-306, 2013.

M. Macedo-viñas, D. Angelis, G. Rohner, P. Safran, E. Stewardson et al., Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs, J Hosp Infect, vol.84, pp.132-139, 2013.

R. E. Nelson, M. Jones, C. Liu, M. H. Samore, M. E. Evans et al., The Impact of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Infections on Postdischarge Health Care Costs and Utilization across Multiple Health Care Systems, Health Serv Res, vol.53, issue.3, pp.5419-5456, 2018.

N. Thampi, A. Showler, L. Burry, A. D. Bai, M. Steinberg et al., Multicenter study of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: Impact of length of stay and intensity of care, Am J Infect Control, vol.43, pp.739-783, 2015.

M. A. Abramson and D. J. Sexton, Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?, Infect Control Hosp Epidemiol, vol.20, pp.408-419, 1999.

C. Pau, F. Ma, M. Ip, and J. You, Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong, Infect Dis Lond Engl, vol.47, pp.283-291, 2015.

H. Sozen, S. Caylak, M. Cetinkaya, B. E. Citil, C. Sahin et al., Clinical and Economic Outcomes Associated with Urinary Tract Infections Caused by Extended Spectrum Beta-lactamase Producing Bacteria in a Tertiary Care Hospital, Stud Ethno-Med, vol.9, pp.173-182, 2015.

R. Leistner, S. Gürntke, C. Sakellariou, L. A. Denkel, A. Bloch et al., Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort, Infection, vol.42, pp.991-998, 2014.

T. A. Gulen, R. Guner, N. Celikbilek, S. Keske, and M. Tasyaran, Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant acinetobacter baumannii, Int J Infect Dis IJID Off Publ Int Soc Infect Dis, vol.38, pp.32-37, 2015.

A. Vasudevan, B. I. Memon, A. Mukhopadhyay, J. Li, and P. A. Tambyah,

A. Cheah, T. Spelman, D. Liew, T. Peel, B. P. Howden et al., Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.19, pp.181-189, 2013.

C. D. Ford, B. K. Lopansri, S. Haydoura, G. Snow, K. K. Dascomb et al., Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia, Infect Control Hosp Epidemiol, vol.36, pp.47-53, 2015.

N. R. Naylor, R. Atun, N. Zhu, K. Kulasabanathan, S. Silva et al., Estimating the burden of antimicrobial resistance: a systematic literature review, Antimicrob Resist Infect Control, vol.7, 2018.

S. Y. Park, J. S. Son, I. H. Oh, J. M. Choi, and M. S. Lee, Clinical impact of methicillin-resistant <Emphasis Type="Italic">Staphylococcus aureus</Emphasis> bacteremia based on propensity scores, Infection, vol.39, p.141, 2011.

S. E. Cosgrove, The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.42, issue.2, pp.82-89, 2006.

E. Larson, Factors associated with variation in estimates of the cost of resistant infections, Med Care, vol.48, pp.767-75, 2010.

T. M. Wozniak, L. Barnsbee, X. J. Lee, and R. E. Pacella, Using the best available data to estimate the cost of antimicrobial resistance: a systematic review, Antimicrob Resist Infect Control, vol.8, p.26, 2019.

S. E. Cosgrove, Y. Qi, K. S. Kaye, S. Harbarth, A. W. Karchmer et al., The Impact of Methicillin Resistance in <span class="italic">Staphylococcus aureus</span> Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges, Infect Control Amp Hosp Epidemiol, vol.26, pp.166-74, 2005.

R. R. Roberts, B. Hota, A. I. Scott, R. D. Foster, S. D. Abbasi et al., Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship, Clin Infect Dis, vol.49, pp.1175-84, 2009.

M. Webb, L. W. Riley, and R. B. Roberts, Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.33, pp.445-52, 2001.

S. J. Chandy, G. S. Naik, V. Balaji, V. Jeyaseelan, K. Thomas et al., High cost burden and health consequences of antibiotic resistance: the price to pay, J Infect Dev Ctries, vol.8, pp.1096-102, 2014.

A. Andreassen, C. M. Jacobsen, B. De-blasio, R. White, I. S. Kristiansen et al., The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway, Antimicrob Resist Infect Control, vol.6, p.74, 2017.

A. Resch, M. Wilke, and C. Fink, The cost of resistance: incremental cost of methicillin-resistant <Emphasis Type="Italic">Staphylococcus aureus</Emphasis> (MRSA) in German hospitals

, Eur J Health Econ, vol.10, pp.287-97, 2009.

K. E. Thorpe, P. Joski, and K. J. Johnston, Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Aff Proj Hope, vol.37, pp.662-671, 2018.

, Stockholm: ECDPC/EMA; 2009. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria, Medicines Agencies (ECDPC/EMA) ECDC/EMEA Joint Technical report

J. Leal, R. Luengo-fernández, A. Gray, S. Petersen, and M. Rayner, Economic burden of cardiovascular diseases in the enlarged European Union, Eur Heart J, vol.27, pp.1610-1619, 2006.

L. Gavaldà, C. Masuet, J. Beltran, M. Garcia, D. Garcia et al., Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection, Infect Control Hosp Epidemiol, vol.27, pp.1264-1270, 2006.

, The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay, Infect Control Hosp Epidemiol, vol.23, pp.106-114, 2002.

, Interventions against antimicrobial resistance: a review of the literature and explortation of modelling cost-effectiveness ; a report prepared for the Global Forum for Health Research

. Repr, Geneva: Global Forum for Health Research, 2001.

S. Larsson, M. Prioux, T. Fasth, A. Ternhag, J. Struwe et al., A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden, Eur J Public Health, vol.29, pp.392-398, 2019.

J. Taylor, M. Hafner, E. Yerushalmi, R. Smith, J. Bellasio et al., Estimating the economic costs of antimicrobial resistance: Model and Results. The Wellcome Trust, 2014.

M. De-kraker, A. J. Stewardson, and S. Harbarth, Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050, PLoS Med, vol.13, 2016.

, Décret n° 2016-1871 du 26 décembre 2016 relatif au traitement de données à caractère personnel dénommé « système national des données de santé, 1871.

P. Tuppin, J. Rudant, P. Constantinou, C. Gastaldi-ménager, A. Rachas et al.,

J. Domin and . Le, Programme de médicalisation des systèmes d'information (PMSI): De l'indicateur de comptabilité hospitalière au mode de tarification, Hist Médecine Santé, pp.69-87, 1982.

A. Guide, . De-productiondu-recueil-d&apos;informationsmédicaliséen, and . Psychiatrie,

A. Guide and . De-productiondes-recueils-d&apos;informations-standardisésde-l&apos;hospitalisation-À-domicile, , 2014.

, Manuel des groupes homogènes de malades, 11ème version de la classification, 6ème révision (11g), 2015.

A. Manuel, , pp.11-2014, 2014.

, World Health Organization. CUMULATIVE OFFICIAL UPDATES TO ICD-10, 2013.

A. Fascicule-de-codage-pour-le, P. , and M. Infectieuses, , 2014.

V. Amrhein, S. Greenland, and B. Mcshane, Scientists rise up against statistical significance, Nature, vol.567, pp.305-312, 2019.

D. Harrington, D. &apos;agostino, R. B. Gatsonis, C. Hogan, J. W. Hunter et al., New Guidelines for Statistical Reporting in the Journal, N Engl J Med, vol.381, pp.285-291, 2019.

G. M. Eliopoulos, S. E. Cosgrove, and Y. Carmeli, The Impact of Antimicrobial Resistance on Health and Economic Outcomes, Clin Infect Dis, vol.36, pp.1433-1440, 2003.

S. Gandra, D. M. Barter, and R. Laxminarayan, Economic burden of antibiotic resistance: how much do we really know?, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.20, pp.973-80, 2014.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, pp.373-83, 1987.

C. Song, C. S. Kim, H. Lee, K. Seo, B. Kim et al., Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database, Nephron Clin Pract, vol.117, pp.379-384, 2011.

P. S. Romano, L. L. Roos, and J. G. Jollis, Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives, J Clin Epidemiol, vol.46, pp.1075-1084, 1993.

H. Quan, V. Sundararajan, P. Halfon, A. Fong, B. Burnand et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care, vol.43, pp.1130-1139, 2005.

A. Bannay, C. Chaignot, P. Blotière, M. Basson, A. Weill et al., The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, Med Care, vol.54, pp.188-94, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

H. Quan, B. Li, C. M. Couris, K. Fushimi, P. Graham et al., Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol, vol.173, pp.676-82, 2011.

J. J. Polder, Age-specific increases in health care costs, Eur J Public Health, vol.12, pp.57-62, 2002.

J. Casqueiro, J. Casqueiro, and C. Alves, Infections in patients with diabetes mellitus: A review of pathogenesis, Indian J Endocrinol Metab, vol.16, pp.27-36, 2012.

L. M. Muller, .. J. Gorter, K. J. Hak, E. Goudzwaard, W. L. Schellevis et al., Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus, Clin Infect Dis, vol.41, pp.281-289, 2005.

H. Armenian, The Case-Control Method: Design and Applications, 2009.

S. E. Cosgrove, Y. Qi, K. S. Kaye, S. Harbarth, A. W. Karchmer et al., The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges, Infect Control Hosp Epidemiol, vol.26, pp.166-74, 2005.

M. De-kraker, M. Wolkewitz, P. G. Davey, and H. Grundmann, Clinical Impact of Antimicrobial Resistance in European Hospitals: Excess Mortality and Length of Hospital Stay Related to Methicillin-Resistant Staphylococcus aureus Bloodstream Infections, Antimicrob Agents Chemother, vol.55, pp.1598-605, 2011.

A. Stewardson, C. Fankhauser, D. Angelis, G. Rohner, P. Safran et al., Burden of bloodstream infection caused by extended-spectrum ?-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model, Infect Control Hosp Epidemiol, vol.34, pp.133-176, 2013.

A. Andreassen, C. M. Jacobsen, B. De-blasio, R. White, I. S. Kristiansen et al., The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway, Antimicrob Resist Infect Control, vol.6, 2017.

M. De-kraker, P. G. Davey, and H. Grundmann, Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe, PLoS Med, vol.8, p.1001104, 2011.

M. Macedo-viñas, G. D. Angelis, P. Rohner, E. Safran, A. Stewardson et al., Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs, J Hosp Infect, vol.84, pp.132-139, 2013.

K. Kaier and U. Frank, In Search of Useful Methods for Measuring Health and Economic Consequences of Antimicrobial Resistance, Clin Infect Dis, vol.57, pp.1220-1222, 2013.

M. Wassenberg, G. A. Wit, . De, B. A. Hout, . Van et al., Quantifying Cost-Effectiveness of Controlling Nosocomial Spread of Antibiotic-Resistant Bacteria: The Case of MRSA, PLOS ONE, vol.5, p.11562, 2010.

C. C. Linnemann, P. Moore, J. L. Staneck, and M. A. Pfaller, Reemergence of epidemic methicillinresistant Staphylococcus aureus in a general hospital associated with changing staphylococcal strains, Am J Med, vol.91, pp.238-244, 1991.

K. B. Laupland, O. Lyytikäinen, M. Sgaard, K. J. Kennedy, J. D. Knudsen et al., The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study, Clin Microbiol Infect, vol.19, pp.465-71, 2013.

E. Mostofsky, M. Lipsitch, and G. Regev-yochay, Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?, J Antimicrob Chemother, vol.66, pp.2199-214, 2011.

M. De-kraker, V. Jarlier, J. Monen, O. E. Heuer, N. Van-de-sande et al., The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System, Clin Microbiol Infect, vol.19, pp.860-868, 2013.

M. Uhart, C. Blein, L. &apos;azou, M. Thomas, L. Durand et al., Costs of dengue in three French territories of the Americas: an analysis of the hospital medical information system (PMSI) database, Eur J Health Econ, vol.17, pp.497-503, 2016.

L. St-guily, J. Borget, I. Vainchtock, A. Rémy, V. Takizawa et al., Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database, Head Neck Oncol, vol.2, p.22, 2010.

S. Leblanc, C. Blein, A. Andremont, P. Bandinelli, and T. Galvain, Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective, Infect Control Hosp Epidemiol, vol.38, pp.906-917, 2017.

C. Jo, Cost-of-illness studies: concepts, scopes, and methods, Clin Mol Hepatol, vol.20, pp.327-364, 2014.

J. P. Burnham, J. H. Kwon, M. A. Olsen, H. M. Babcock, and M. H. Kollef, Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection, Infect Control Hosp Epidemiol, vol.39, pp.12-21, 2018.

N. M. Quezada-joaquin, D. J. Diekema, E. N. Perencevich, G. Bailey, P. L. Winokur et al., Long-term risk for readmission, methicillin-resistant Staphylococcus aureus (MRSA) infection, and death among MRSA-colonized veterans, Antimicrob Agents Chemother, vol.57, pp.1169-72, 2013.

K. Inagaki, J. Lucar, C. Blackshear, and C. V. Hobbs, Methicillin-susceptible and Methicillinresistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, Inhospital Mortality, Length of Stay, and Cost in the United States, Clin Infect Dis. XX:XX

S. H. Macvane, L. O. Tuttle, and D. P. Nicolau, Demography and burden of care associated with patients readmitted for urinary tract infection, J Microbiol Immunol Infect, vol.48, pp.517-541, 2015.

J. A. Messina, E. Cober, S. S. Richter, F. Perez, R. A. Salata et al., Hospital Readmissions in Patients with Carbapenem-Resistant Klebsiella pneumoniae, Infect Control Hosp Epidemiol, vol.37, pp.281-289, 2016.

A. Sentís, C. González, M. Montero, M. Herranz, C. Hidalgo et al., Risk of hospital

C. B. Emerson, L. M. Eyzaguirre, J. S. Albrecht, A. C. Comer, A. D. Harris et al., Healthcare-Associated Infection and Hospital Readmission, Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am, vol.33, pp.539-583, 2012.

L. K. Yaw, J. O. Robinson, and K. M. Ho, A comparison of long-term outcomes after meticillinresistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study, Lancet Infect Dis, vol.14, pp.967-75, 2014.

M. D. Zilberberg, B. H. Nathanson, K. Sulham, W. Fan, and A. F. Shorr, 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study, Antimicrob Resist Infect Control, vol.6, p.1, 2017.

L. B. Johnson, M. O. Almoujahed, K. Ilg, L. Maolood, and R. Khatib, Staphylococcus aureus Bacteremia: Compliance with Standard Treatment, Long-term Outcome and Predictors of Relapse, Scand J Infect Dis, vol.35, pp.782-791, 2003.

D. J. Anderson, K. S. Kaye, L. F. Chen, K. E. Schmader, Y. Choi et al., Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study, PloS One, vol.4, p.8305, 2009.

S. T. Micek, M. H. Kollef, M. D. Zilberberg, M. D. Zilberberg, and A. F. Shorr, Risk factors for 30-day readmission among patients with culture-positive severe sepsis and septic shock: A retrospective cohort study, J Hosp Med, vol.10, pp.678-85, 2015.

A. J. Moore, A. W. Blom, M. R. Whitehouse, and R. Gooberman-hill, Deep prosthetic joint infection: a qualitative study of the impact on patients and their experiences of revision surgery, BMJ Open, vol.5, p.9495, 2015.

S. Y. Lim, D. Pannikath, and K. Nugent, A retrospective study of septic arthritis in a tertiary hospital in West Texas with high rates of methicillin-resistant Staphylococcus aureus infection

, Rheumatol Int, vol.35, pp.1251-1257, 2015.

J. D. Whitehouse, N. D. Friedman, K. B. Kirkland, W. J. Richardson, and D. J. Sexton, The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost, Infect Control Hosp Epidemiol, vol.23, pp.183-192, 2002.

A. E. Andersson, I. Bergh, J. Karlsson, and K. Nilsson, Patients' experiences of acquiring a deep surgical site infection: An interview study, Am J Infect Control, vol.38, pp.711-718, 2010.

C. C. Butler, S. Hillier, Z. Roberts, F. Dunstan, A. Howard et al., Antibiotic-resistant infections in primary care are symptomatic for longer and increase workload, Br J Gen Pract, vol.7, 2006.

M. F. Alam, D. Cohen, C. Butler, F. Dunstan, Z. Roberts et al., The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice, Int J Antimicrob Agents, vol.33, pp.255-262, 2009.

K. E. Thorpe, P. Joski, and K. J. Johnston, Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually, Health Aff (Millwood), vol.37, pp.662-671, 2018.

C. Brzinsky-fay, U. Kohler, and M. Luniak, Sequence Analysis with Stata, Stata J Promot Commun Stat Stata, vol.6, pp.435-60, 2006.

A. Gabadinho, G. Ritschard, N. S. Müller, and M. Studer, Analyzing and Visualizing State Sequences in R with TraMineR, J Stat Softw, vol.40, pp.1-37, 2011.

L. Meur, N. Vigneau, C. Lefort, M. Lebbah, S. Jais et al., Categorical state sequence analysis and regression tree to identify determinants of care trajectory in chronic disease: Example of end-stage renal disease, Stat Methods Med Res, vol.28, pp.1731-1771, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01792740

J. Roux, O. Grimaud, and E. Leray, Use of state sequence analysis for care pathway analysis: The example of multiple sclerosis, Stat Methods Med Res, vol.28, pp.1651-63, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01798652

A. Abbott and J. Forrest, Optimal Matching Methods for Historical Sequences, J Interdiscip Hist, vol.16, p.471, 1986.

L. Lesnard and T. De-saint-pol, Introduction aux méthodes d'appariement optimal (Optimal Matching Analysis), Bull Sociol Methodol Méthodologie Sociol, vol.90, pp.5-25, 2006.

D. Sankoff, J. B. Kruskal, B. Laboratories, and M. Hill, An Overview of Sequence Comparison: Time Warps, String Edits, and Macromolecules, SIAM Rev, vol.38, 1983.

J. M. Hoebert, P. C. Souverein, A. K. Mantel-teeuwisse, H. Leufkens, and L. Van-dijk, Reimbursement Restriction and Moderate Decrease in Benzodiazepine Use in General Practice

, Ann Fam Med, vol.10, pp.42-51, 2012.

E. Lebarbier and T. Mary-huard, Classification non supervisée, p.51

M. Studer, WeightedCluster Library Manual: A practical guide to creating typologies of trajectories in the social sciences with R, p.34

P. J. Rousseeuw, Silhouettes: A graphical aid to the interpretation and validation of cluster analysis, J Comput Appl Math, vol.20, pp.53-65, 1987.

L. Lovmar, A. Ahlford, M. Jonsson, and A. Syvänen, Silhouette scores for assessment of SNP genotype clusters, BMC Genomics, vol.6, p.35, 2005.

R. Blundell and M. C. Dias, Alternative Approaches to Evaluation in Empirical Microeconomics, J Hum Resour, vol.44, pp.565-640, 2009.

J. D. Angrist and J. Pischke, Mostly Harmless Econometrics: An Empiricist's Companion, 2008.

O. Ashenfelter and D. Card, Using the Longitudinal Structure of Earnings to Estimate the Effect of Training Programs, Rev Econ Stat, vol.67, pp.648-60, 1985.

A. Abadie, Semiparametric Difference-in-Differences Estimators, Rev Econ Stud, vol.72, pp.1-19, 2005.

K. Liang and S. L. Zeger, Longitudinal data analysis using generalized linear models, Biom, vol.73, pp.13-22, 1986.

L. Grammatico-guillon, S. Baron, S. Gettner, A. I. Lecuyer, C. Gaborit et al., Surveillance hospitalière des infections ostéo-articulaires en France: analyse des données médico-administratives, Bull Epidémiologique Hebd, pp.4-5, 2013.

S. M. Wallace, B. I. Walton, R. K. Kharbanda, R. Hardy, A. P. Wilson et al., Mortality from infective endocarditis: clinical predictors of outcome, Heart, vol.88, pp.53-60, 2002.

A. Cresti, M. Chiavarelli, M. Scalese, C. Nencioni, S. Valentini et al., Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study, Cardiovasc Diagn Ther, vol.7, pp.27-35, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01521361

P. S. Hussey, M. S. Ridgely, and M. B. Rosenthal, The PROMETHEUS Bundled Payment Experiment: Slow Start Shows Problems In Implementing New Payment Models, Health Aff (Millwood), vol.30, pp.2116-2140, 2011.

, Centers for Medicare & Medicaid Services

, Comprehensive Care for Joint Replacement Payment Model for Acute Care Hospitals Furnishing Lower Extremity Joint Replacement Services. Final rule, Fed Regist, vol.80, pp.73273-554, 2015.

M. B. Buntin and A. M. Zaslavsky, Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures, J Health Econ, vol.23, pp.525-567, 2004.

W. G. Manning and J. Mullahy, Estimating log models: to transform or not to transform?, J Health Econ, vol.20, pp.461-94, 2001.

J. Beyene and R. Moineddin, Methods for confidence interval estimation of a ratio parameter with application to location quotients, BMC Med Res Methodol, vol.5, p.32, 2005.

J. S. Albrecht, J. F. Slejko, D. M. Stein, and G. S. Smith, Treatment Charges for Traumatic Brain Injury Among Older Adults at a Trauma Center, J Head Trauma Rehabil, vol.32, pp.45-53, 2017.

M. Griswold and J. Lipscomb, Analyzing Health Care Costs: A Comparison of Statistical Methods Motivated by Medicare Colorectal Cancer Charges, p.23, 20041.

H. Autorité-de-santé, Algorithme d'aide à la décision d'orientation des patients en HAD, p.148, 2017.

A. H. Norris, N. K. Shrestha, G. M. Allison, S. C. Keller, K. P. Bhavan et al., IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya, p.35, 2018.

E. G. Muldoon, K. Switkowski, A. Tice, D. R. Snydman, and G. M. Allison, A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT), Infect Dis, vol.47, pp.39-45, 2015.

J. A. Paladino and D. Poretz, Outpatient Parenteral Antimicrobial Therapy Today, Clin Infect Dis, vol.51, pp.198-208, 2010.

S. Esposito, S. Noviello, S. Leone, A. Tice, G. Seibold et al., Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison, Int J Antimicrob Agents, vol.24, pp.473-481, 2004.

L. Bernard, . El-hajj, B. Pron, A. Lotthé, V. Gleizes et al., Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost, J Clin Pharm Ther, vol.26, pp.445-51, 2001.

, Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements d'hospitalisation à domicile (HAD), Réseau d'alerte, d'investigation et de surveillance des infections nosocomiales, 2019.

A. D. Tice, S. J. Rehm, J. R. Dalovisio, J. S. Bradley, L. P. Martinelli et al., Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy, Clin Infect Dis, vol.38, pp.1651-71, 2004.

J. M. Pericàs, J. Llopis, V. González-ramallo, M. Á. Goenaga, P. Muñoz et al., Outpatient Parenteral Antibiotic Treatment (OPAT) for Infective Endocarditis: a Prospective Cohort Study From the GAMES Cohort, Clin Infect Dis Off Publ Infect Dis Soc Am, 2019.

G. Habib, P. Lancellotti, M. J. Antunes, M. G. Bongiorni, J. Casalta et al., of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM), Eur Heart J, vol.36, pp.3075-128, 2015.

R. A. Seaton, E. Sharp, V. Bezlyak, and C. J. Weir, Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections, Int J Antimicrob Agents, vol.38, pp.243-251, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00722868

A. Gomila, E. Shaw, J. Carratalà, L. Leibovici, C. Tebé et al., Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections, Antimicrob Resist Infect Control, vol.7, p.111, 2018.

S. Bischoff, T. Walter, M. Gerigk, M. Ebert, and R. Vogelmann, Infect Dis, vol.18, p.56, 2018.

E. M. Graffunder and R. A. Venezia, Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials, J Antimicrob Chemother, vol.49, pp.999-1005, 2002.

P. Rattanaumpawan, P. Tolomeo, W. B. Bilker, N. O. Fishman, and E. Lautenbach, Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections, J Hosp Infect, vol.76, pp.324-331, 2010.

C. G. Mchugh and L. W. Riley, Risk Factors and Costs Associated With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections, Infect Control Hosp Epidemiol, vol.25, pp.425-455, 2004.

C. C. Fethke, I. M. Smith, and N. Johnson, Risk" Factors Affecting Readmission of the Elderly into the Health Care System, Med Care, vol.24, pp.429-466, 1986.

D. Kansagara, H. Englander, A. Salanitro, D. Kagen, C. Theobald et al., Risk Prediction Models for Hospital Readmission: A Systematic Review, JAMA, vol.306, pp.1688-98, 2011.

L. J. Strausbaugh and C. L. Joseph, The Burden of Infection in Long-Term Care, Infect Control Hosp Epidemiol, vol.21, pp.674-683, 2000.

E. O&apos;fallon, A. Pop-vicas, D. &apos;agata, and E. , The Emerging Threat of Multidrug-Resistant Gram-Negative Organisms in Long-Term Care Facilities, J Gerontol Ser A, vol.64, pp.138-179, 2009.

E. Toubes, K. Singh, D. Yin, R. Lyu, N. Glick et al., Risk Factors for Antibiotic-Resistant Infection and Treatment Outcomes among Hospitalized Patients Transferred from Long-Term Care Facilities: Does Antimicrobial Choice Make a Difference?, Clin Infect Dis, vol.36, pp.724-754, 2003.

C. Hübner and S. Flessa, Reimbursement for Hospital-acquired Infections with Multidrug Resistant Organisms in German DRG System, Econ Sociol, vol.9, pp.111-119, 2016.

D. Lepelletier, S. Ferréol, D. Villers, and H. Richet, Infections nosocomiales à Staphylococcus aureus résistant à la méthicilline en réanimation médicale polyvalente : facteurs de risque, morbidité et impact économique, Pathol Biol, vol.52, pp.474-483, 2004.

, Rapport public annuel 2019 de la cour des comptes : La politique de prévention des infections associées aux soins : une nouvelle étape à franchir, Cour des comptes, 2019.

L. Coz, P. Carlet, J. Roblot, F. Pulcini, and C. , Human resources needed to perform antimicrobial stewardship teams' activities in French hospitals, Med Mal Infect, vol.46, pp.200-206, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817498

M. R. Haverkate, L. Derde, C. Brun-buisson, M. Bonten, and M. Bootsma, Duration of colonization with antimicrobial-resistant bacteria after ICU discharge, Intensive Care Med, vol.40, pp.564-71, 2014.

A. March, R. Aschbacher, H. Dhanji, D. M. Livermore, A. Böttcher et al., Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria, Clin Microbiol Infect, vol.16, pp.934-978, 2010.

A. Chapman, S. Dixon, D. Andrews, P. J. Lillie, R. Bazaz et al., Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective, J Antimicrob Chemother, vol.64, pp.1316-1340, 2009.

M. Mackenzie, N. Rae, and D. Nathwani, Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: A review of the last decade, Int J Antimicrob Agents, vol.43, pp.7-16, 2014.

L. Mauro, Dix ans d'hospitalisation à domicile, Doss DREES, vol.21, 2006.

. Léotoing-l-de, F. Barbier, A. Dinh, D. Breilh, G. Chaize et al., French hospital discharge database (PMSI) and bacterial resistance: Is coding adapted to hospital epidemiology?, Médecine Mal Infect, vol.48, pp.465-73, 2018.

V. B. Haley, C. Van-antwerpen, B. Tserenpuntsag, K. A. Gase, P. Hazamy et al., Use of administrative data in efficient auditing of hospital-acquired surgical site infections, Infect Control Hosp Epidemiol, vol.33, pp.565-71, 2009.

L. Grammatico-guillon, S. Baron, S. Gettner, A. Lecuyer, C. Gaborit et al., Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes, J Hosp Infect, vol.82, pp.40-48, 2012.

M. Opatowski, P. Tuppin, K. Cosker, M. Touat, G. De-lagasnerie et al., Hospitalisations with infections related to antimicrobial-resistant bacteria from the French nationwide hospital discharge database, Epidemiol Infect, 2016.

A. Shiell, K. Gerard, and C. Donaldson, Cost of illness studies: An aid to decision-making?, Health Policy, vol.8, pp.317-340, 1987.

S. Byford, D. J. Torgerson, and J. Raftery, Economic note: cost of illness studies, BMJ, vol.320, pp.1335-1335, 2000.

G. Currie, Are cost of injury studies useful?, Inj Prev, vol.6, pp.175-181, 2000.

M. Drummond, Cost-of-Illness Studies, PharmacoEconomics, vol.2, pp.1-4, 1992.